Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

LOS ANGELES, Dec. 30, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Novavax, Inc. ("Novavax" or the "Company") (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021 , inclusive (the "Class Period").

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Novavax, Inc. (NVAX) Investors

NVAX stock hasn't had and easy run but FDA approval is closer than ever and may come on the heels of WHO approvals The post Novavax is In Position to Move Upward While Awaiting More Good News appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.

Novavax is In Position to Move Upward While Awaiting More Good News

NEW ORLEANS, Dec. 29, 2021 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until January 11, 2022 to file lead plaintiff applications in a securities class action lawsuit against Novavax, Inc. (NasdaqGS: NVAX), if they purchased the Company's securities between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Maryland.

NOVAVAX SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Novavax, Inc. - NVAX

NEW YORK, Dec. 29, 2021 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novavax, Inc. (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"), of the important January 11, 2022 lead plaintiff deadline. SO WHAT: If you purchased Novavax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

FINAL DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Novavax, Inc. Investors with Losses to Secure Counsel Before Important January 11 Deadline in Securities Class Action - NVAX

Novavax (NVAX) secures approval in India for emergency use of its COVID-19 vaccine.

Novavax (NVAX) COVID Jab Gets Nod for Emergency Use in India

Boston, Massachusetts--(Newsfile Corp. - December 29, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Novavax, Inc. (NASDAQ: NVAX). The case is currently in the lead plaintiff stage. Investors who purchased NVAX securities between March 2, 2021 and October 19, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Novavax for more information. Investors may also email investors@tenlaw.com or call...

NVAX ALERT: Thornton Law Firm Reminds Novavax, Inc. Investors of Securities Class Action Lawsuit

Shares of Novavax Inc. NVAX, +4.34% hiked up 2.9% in morning trading Tuesday, after the Maryland-based biotechnology company and vaccine manufacture Serum Institute of India Pvt. Ltd. said Novavax's protein-based COVID-19 vaccine, Covovax, has been granted Emergency Use Authorization (EUA) in India by the Drugs Controller General of India.

Novavax's stock rallies after its COVID-19 vaccine is granted EUA in India

GAITHERSBURG, Md. and PUNE, India, Dec. 28, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt.

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in India

Covid-19 vaccine developer Novavax's stock (NASDAQ: NVAX) declined by about 9% over the last week (five trading days), compared to the S&P 500 which remains up by about 1% over the same period. While there has actually been some positive news for Novavax, which indicated that its Covid-19 vaccine.

What's New For Novavax Stock?

Alight

A Biotech Company and an Under-The-Radar Cloud Transformation Stock to Round Out the Year

Top Stock Picks for Week of December 27, 2021

Novavax, Inc. (NASDAQ:NVAX) shares are trading lower Monday, slightly falling below a pattern the stock has been trading in. On Thursday, the company said it expanded a license agreement for its NVX-CoV2373 recombinant nanoparticle protein-based COVID-19 vaccine with SK Bioscience Co. Novavax was down 10.97% at $157.80 at market close Monday.

Novavax Falls Below Support: What Does This Mean For The Vaccine Stock?

San Francisco, California--(Newsfile Corp. - December 27, 2021) - Hagens Berman urges Novavax, Inc. (NASDAQ: NVAX) investors with significant losses to submit your losses now. Class Period: Mar. 2, 2021 - Oct. 19, 2021Lead Plaintiff Deadline: Jan. 11, 2022Visit: www.hbsslaw.com/investor-fraud/NVAX Contact An Attorney Now: NVAX@hbsslaw.com 844-916-0895Novavax, Inc. (NVAX) Securities Fraud Class Action: The lawsuit alleges that Defendants misrepresented Novavax's progress toward successfully developing its COVID-19 vacc

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Novavax (NVAX) Investors Jan. 11th Deadline in Securities Class Action, Encourages Investors with Losses to Contact Firm's Attorneys

Here's what investors may want to know about Novavax and NVAX stock, as shares continue to decline despite key catalysts on the horizon. The post NVAX Stock Dips Ahead of Potential Novavax Catalyst.

NVAX Stock Dips Ahead of Potential Novavax Catalyst. What to Know.

Ping Identity Holding Corp

4 New Stocks I'll Likely Add to My Portfolio in 2022

Radnor, Pennsylvania--(Newsfile Corp. - December 25, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Novavax, Inc. ("Novavax") (NASDAQ: NVAX). The action charges Novavax with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Novavax's materially misleading statements, Novavax investors have suffered significant losses.

Kessler Topaz Meltzer & Check, LLP Reminds Novavax, Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm

AstraZeneca

Moderna

Pfizer

Could these vaccine stocks be prime additions to your portfolio today?

Good Stocks To Buy Right Now? 4 Vaccine Stocks To Check Out

RADNOR, Pa., Dec. 23, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Novavax, Inc. ("Novavax") (NASDAQ: NVAX).

NVAX CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces to Novavax, Inc. of Deadline in Securities Fraud Class Action Lawsuit

GAITHERSBURG, Md., Dec. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-based SK Group, today announced the expansion of the companies' collaboration and license agreements for NVX-CoV2373, Novavax' recombinant nanoparticle protein-based COVID-19 vaccine.

Novavax and SK bioscience Expand Manufacturing Agreement

Pfizer, AstraZeneca, and Novavax will be important players in the next stages of the world's battle against the pandemic.

3 COVID Stocks to Fight Omicron

Despite NVAX stock being lower, Novavax announced promising data based on initial results of a study. Here's what you should know.

NVAX Stock: 5 Things to Know About Novavax's Omicron-Fighting News

Novavax's (NVAX) protein-based COVID vaccine shows a cross-reactivity response against the Omicron variant. It will also start clinical studies on an Omicron-specific vaccine in first-quarter 2022.

Novavax (NVAX) COVID-19 Booster Jab Effective Against Omicron

Novavax stock climbed early Thursday as the U.S. biotech said its Covid-19 vaccine produces an immune response to the Omicron variant, according to initial data.

Novavax Vaccine Produces Immune Response to Omicron.

Novavax Inc (NASDAQ: NVAX) said its two-dose COVID-19 vaccine effectively generates an immune response against the Omicron variant, according to early data. Though the company said neutralization against the Omicron variant was "4-fold lower" than it was against the original strain of the virus, suggesting that a booster shot or a new Omicron-specific vaccine would be beneficial.

Early Data Shows Novavax's COVID-19 Vaccine Triggers Immune Response To Omicron

Novavax said a third dose of its vaccine increased antibodies against omicron 73.5-fold from its initial two shots.

Novavax Covid Vaccine Provides Antibody Response Against Omicron, Data Suggests

Novavax Inc. shares were volatile in the extended session Wednesday after the biotech drug maker said initial data showed its COVID-19 vaccine booster showed immune responses against the omicron variant.

News for Novavax Stock (NVAX)